Work

P75.03 KEYNOTE-U01: A Phase 2 Umbrella Study of Investigational Agents Plus Pembrolizumab-Based Therapy for Advanced NSCLC

Year: 2021

Type: conference-abstract

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2021.01.1037

Authors: S. Rao, S. Arnold, D. Carbone, R. Salgia, A. Tsao, J. Niu, C. Aggarwal, K.H. Dragnev, M. Awad, J. Gainor, M. Gubens, V. Velcheti, L. Telliho, O.O. Akala, E. Chartash, J. Stevenson

Institutions: MedStar Franklin Square Medical Center, University of Kentucky HealthCare, Markey Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, City Of Hope National Medical Center, City of Hope, The University of Texas MD Anderson Cancer Center, Banner MD Anderson Cancer Center, Abramson Cancer Center, University of Pennsylvania, Dartmouth–Hitchcock Medical Center, Dartmouth Cancer Center, Dana-Farber Cancer Institute, Massachusetts General Hospital, University of California, San Francisco, New York University, Merck & Co., Inc., Rahway, NJ, USA (United States), Cleveland Clinic

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3137800304

Cites:

Cited by:

Related to: 10